I-125 Seeds Permanent Interstitial Brachytherapy to Treat Malignant Sublingual Gland Tumors: A Clinical Retrospective Study
Yan Shi,Ming-wei Huang,Tie-li Song,Xiao-ming Lv,Jie Zhang,Jian-guo Zhang
DOI: https://doi.org/10.1016/j.brachy.2016.04.105
IF: 2.441
2016-01-01
Brachytherapy
Abstract:PurposeThe goal of the study is to conclude local control rate, overall survival of brachytherapy using I-125 radioactive seeds for treating malignant sublingual gland tumors.Materials and MethodsFifty-eight patients of malignant tumor derived from sublingual gland, either primary or recurrent, including twenty-seven male and thirty-one female, were collected in the study. The median age was 53.5, ranging from 24 to 78. There were 44 adenoid cystic carcinoma, 7 mucoepidermoid carcinoma, 4 adenoid carcinoma, 2 malignant pleomorphic adenoma and 1 acinic cell carcinoma. The stage for patients, 60.5% was for early state (stage I and II), 39.5% was for late stage (stage III and IV). Forty-three patients were treated by surgical resection combined adjuvant brachytherapy and fifteen patients were treated by brachytherapy alone. Twenty-eight were local tumor resection and fifteen were composite procedures, including six segmental mandibulectomy, five marginal jaw resection and four submandibular gland resection. Selective neck resection was performed in ten patients. Brachytherapy were designed by treatment planning system. Patients were implanted a mean amount of 51 I-125 radioactive seeds, ranging from 8∼147 seeds. The total seeds activity was 24.5mCi (1361.6MBq) on average. The prescription dose ranged from 60∼140Gy. Each patient received quality verification and was followed up. Kaplan-Meier analysis were performed.ResultsFifty-eight patients were followed up for 8∼167 months, median time was 49 months. There were twelve local failures and six of which caused death, ten distant metastasis and five of which caused death. Three patients suffered tongue squamous cell cancer 2-6 years after brachytherapy, sebsequently performed tumor resection and free flap reconstruction, one of whom eventually died of tongue cancer after several times surgery. The 1-year, 3-year and 5-year local control rate was 94.8%, 87.5% and 78.7% respectively. Kaplan-Meier analysis was used for overall survival (OS) and disease free survival (DFS). OS for 3-year, 5-year and 10-year was 85.7%, 80% and 73.4% respectively. DFS for 3-year, 5-year and 10-year was 83.5%, 79.5% and 71.6% respectively. Univariate analysis showed that stage, metastasis, and surgery had significant impact on OS (p=0.012, p<0.001, p<0.001). Of late stage patient, surgery combined adjuvant brachytherapy increased OS and DFS significantly than brachytherapy alone (p<0.001), whereas of early stage patients, surgery performed or not didn't show significant impact on OS (p=0.315). Gender, recurrent tumor and pathology showed no impact on OS. Multivariate analysis demonstrated that distant metastasis and treatment style were predictors for OS (p=0.011, p=0.010) and DFS (p=0.004, p=0.031). One patient suffered from osteomyelitis, two patients suffered from post-brachytherapy infection and healed eventually. No severe xerostomia and limitation of mouth opening was observed.Conclusions PurposeThe goal of the study is to conclude local control rate, overall survival of brachytherapy using I-125 radioactive seeds for treating malignant sublingual gland tumors. The goal of the study is to conclude local control rate, overall survival of brachytherapy using I-125 radioactive seeds for treating malignant sublingual gland tumors. Materials and MethodsFifty-eight patients of malignant tumor derived from sublingual gland, either primary or recurrent, including twenty-seven male and thirty-one female, were collected in the study. The median age was 53.5, ranging from 24 to 78. There were 44 adenoid cystic carcinoma, 7 mucoepidermoid carcinoma, 4 adenoid carcinoma, 2 malignant pleomorphic adenoma and 1 acinic cell carcinoma. The stage for patients, 60.5% was for early state (stage I and II), 39.5% was for late stage (stage III and IV). Forty-three patients were treated by surgical resection combined adjuvant brachytherapy and fifteen patients were treated by brachytherapy alone. Twenty-eight were local tumor resection and fifteen were composite procedures, including six segmental mandibulectomy, five marginal jaw resection and four submandibular gland resection. Selective neck resection was performed in ten patients. Brachytherapy were designed by treatment planning system. Patients were implanted a mean amount of 51 I-125 radioactive seeds, ranging from 8∼147 seeds. The total seeds activity was 24.5mCi (1361.6MBq) on average. The prescription dose ranged from 60∼140Gy. Each patient received quality verification and was followed up. Kaplan-Meier analysis were performed. Fifty-eight patients of malignant tumor derived from sublingual gland, either primary or recurrent, including twenty-seven male and thirty-one female, were collected in the study. The median age was 53.5, ranging from 24 to 78. There were 44 adenoid cystic carcinoma, 7 mucoepidermoid carcinoma, 4 adenoid carcinoma, 2 malignant pleomorphic adenoma and 1 acinic cell carcinoma. The stage for patients, 60.5% was for early state (stage I and II), 39.5% was for late stage (stage III and IV). Forty-three patients were treated by surgical resection combined adjuvant brachytherapy and fifteen patients were treated by brachytherapy alone. Twenty-eight were local tumor resection and fifteen were composite procedures, including six segmental mandibulectomy, five marginal jaw resection and four submandibular gland resection. Selective neck resection was performed in ten patients. Brachytherapy were designed by treatment planning system. Patients were implanted a mean amount of 51 I-125 radioactive seeds, ranging from 8∼147 seeds. The total seeds activity was 24.5mCi (1361.6MBq) on average. The prescription dose ranged from 60∼140Gy. Each patient received quality verification and was followed up. Kaplan-Meier analysis were performed. ResultsFifty-eight patients were followed up for 8∼167 months, median time was 49 months. There were twelve local failures and six of which caused death, ten distant metastasis and five of which caused death. Three patients suffered tongue squamous cell cancer 2-6 years after brachytherapy, sebsequently performed tumor resection and free flap reconstruction, one of whom eventually died of tongue cancer after several times surgery. The 1-year, 3-year and 5-year local control rate was 94.8%, 87.5% and 78.7% respectively. Kaplan-Meier analysis was used for overall survival (OS) and disease free survival (DFS). OS for 3-year, 5-year and 10-year was 85.7%, 80% and 73.4% respectively. DFS for 3-year, 5-year and 10-year was 83.5%, 79.5% and 71.6% respectively. Univariate analysis showed that stage, metastasis, and surgery had significant impact on OS (p=0.012, p<0.001, p<0.001). Of late stage patient, surgery combined adjuvant brachytherapy increased OS and DFS significantly than brachytherapy alone (p<0.001), whereas of early stage patients, surgery performed or not didn't show significant impact on OS (p=0.315). Gender, recurrent tumor and pathology showed no impact on OS. Multivariate analysis demonstrated that distant metastasis and treatment style were predictors for OS (p=0.011, p=0.010) and DFS (p=0.004, p=0.031). One patient suffered from osteomyelitis, two patients suffered from post-brachytherapy infection and healed eventually. No severe xerostomia and limitation of mouth opening was observed. Fifty-eight patients were followed up for 8∼167 months, median time was 49 months. There were twelve local failures and six of which caused death, ten distant metastasis and five of which caused death. Three patients suffered tongue squamous cell cancer 2-6 years after brachytherapy, sebsequently performed tumor resection and free flap reconstruction, one of whom eventually died of tongue cancer after several times surgery. The 1-year, 3-year and 5-year local control rate was 94.8%, 87.5% and 78.7% respectively. Kaplan-Meier analysis was used for overall survival (OS) and disease free survival (DFS). OS for 3-year, 5-year and 10-year was 85.7%, 80% and 73.4% respectively. DFS for 3-year, 5-year and 10-year was 83.5%, 79.5% and 71.6% respectively. Univariate analysis showed that stage, metastasis, and surgery had significant impact on OS (p=0.012, p<0.001, p<0.001). Of late stage patient, surgery combined adjuvant brachytherapy increased OS and DFS significantly than brachytherapy alone (p<0.001), whereas of early stage patients, surgery performed or not didn't show significant impact on OS (p=0.315). Gender, recurrent tumor and pathology showed no impact on OS. Multivariate analysis demonstrated that distant metastasis and treatment style were predictors for OS (p=0.011, p=0.010) and DFS (p=0.004, p=0.031). One patient suffered from osteomyelitis, two patients suffered from post-brachytherapy infection and healed eventually. No severe xerostomia and limitation of mouth opening was observed. Conclusions